⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INCY News
Incyte Genomics Inc
Form 8-K
sec.gov
INCY
Treg Cell-Based Therapies Clinical Trial Pipeline Appears Robust With 29+ Key Pharma Companies Actively Working in the Domain | DelveInsight
globenewswire.com
RAPT
SANG
INCY
ABBV
ARCT
AMGN
CHKP
PFE
LLY
SCLX
SNY
UCB
BIIB
NVS
VTRS
BMY
ABSI
ALEC
GSK
IONS
CLNN
ANNX
MED
GAM
VRTX
EXC
BLRX
Form 8-K
sec.gov
INCY
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
businesswire.com
INCY
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ®/Minjuvi ®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
businesswire.com
INCY
Cutaneous T-Cell Lymphoma Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight
globenewswire.com
SNGX
IPHA
BMY
NKTX
AZN
MRK
TAK
NVS
GMAB
ABBV
BIIB
CRSP
INCY
ALKS
PFE
REGN
GILD
AMGN
Incyte da a conocer los datos a largo plazo de 24 semanas del ensayo de fase III TRuE-AD4 de la crema Opzelura ® (ruxolitinib) en adultos con dermatitis atópica moderada
businesswire.com
INCY
Incyte maakt langetermijngegevens van 24 weken bekend uit de Fase 3 TRuE-AD4-studie van Opzelura ® (ruxolitinib) crème bij volwassenen met matige atopische dermatitis
businesswire.com
INCY
Incyte annonce les données à long terme sur 24 semaines de l'essai de phase 3 TRuE-AD4 sur la crème Opzelura ® (ruxolitinib) chez les adultes atteints de dermatite atopique modérée
businesswire.com
INCY
Incyte annuncia dati a lungo termine relativi allo studio di fase 3 TRuE-AD4l di 24 settimana sulla crema Opzelura ® (ruxolitinib) in soggetti adulti affetti da dermatite atopica moderata
businesswire.com
INCY